$SCNX

EXCLUSIVE: Scienture Expands Access To Arbli Losartan Oral Suspension With Addition To Formularies Covering 100 Million Lives - Scienture Holdings (NASDAQ:SCNX)

Scienture Holdings, Inc. ( NASDAQ:SCNX ) announced on Tuesday that Arbli ( losartan potassium ) Oral Suspension, 10 mg/mL, has been added to the formularies of key national payors, expanding access through both multiple commercial coverage and Medicare supplement plans.

Original reporting
Benzinga · Vandana Singh
Published Nov 4, 2025, 12:51 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Nov 4, 2025, 1:01 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
EXCLUSIVE: Scienture Expands Access To Arbli Losartan Oral Suspension With Addition To Formularies Covering 100 Million Lives - Scienture Holdings (NASDAQ:SCNX) — source image
Decision brief

The 30-second read

$SCNXBullishMed
01

Why it matters

The formulary inclusion is a significant milestone that could lead to increased prescriptions and revenue, positively influencing stock performance.

02

Market read

The news is highly relevant for investors holding SCNX, with potential sector-wide implications for biotech and pharma stocks.

03

What to watch

Possible delays in formulary approval processes, reimbursement challenges, or market saturation could temper positive effects.

Timing: Immediate to short-term (next 1-3 months)

Background

Scienture's strategic focus on expanding formulary access aims to boost sales of Arbli Losartan, a key product for hypertension management.

Company-level read

Ticker impact

$SCNXBullishHigh confidence
Context

The news pertains directly to Scienture Holdings (SCNX), indicating potential positive impact due to increased formulary coverage.

Expected impact

Moderate upward movement in SCNX stock price over the short to medium term.

Evidence & confidence

The inclusion in key formularies directly enhances product accessibility, likely translating into revenue growth. The sentiment score and recent bullish ticker sentiment support this outlook.

Market effects

Potential positive impact on biotech and pharmaceutical sectors, especially companies with similar products or market access strategies.

Likely positive in the US healthcare market, where formulary access significantly influences sales.

Limited; primarily relevant to US market and healthcare payor landscape.

Counterpoint

Potential overestimation of short-term impact; formulary additions do not guarantee sales growth if other factors (e.g., competition, pricing) are unfavorable.

Key entities

  • Scienture Holdings

    A healthcare company specializing in pharmaceutical products.

  • Arbli Losartan Oral Suspension

    A medication used to treat hypertension.

  • Major Payors

    Key insurance providers and healthcare payors covering the medication.

Related articles

$SCNXMed

Scienture Announces Commercial Inventory Readiness For REZENOPY Naloxone Nasal Spray; Stock Up

Scienture Holdings (SCNX) said it completed manufacturing commercial launch inventory for REZENOPY naloxone nasal spray 10 mg and will start shipments to U.S. wholesalers in July, with broad availability expected in August. The company cited IQVIA data valuing the U.S. naloxone market at about $144 million annually and said payer access could cover over 100 million lives.

$SCNXMedAI 9/10

SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041

Scienture Holdings (NASDAQ: SCNX) said the U.S. Patent and Trademark Office granted U.S. Patent No. 12,622,903 B2 covering REZENOPY™ (naloxone HCl) Nasal Spray 10 mg, effective May 12, 2026 and expiring Feb. 5, 2041. The patent was issued to Summit Biosciences, a subsidiary of Kindeva. Scienture’s subsidiary has exclusive U.S. commercialization rights; REZENOPY™ was FDA-approved April 19, 2024. IQVIA data cited: ~$141M annual U.S. naloxone sales and 9.4M units (MAT Jan 2026).

$ACIMed

Albertsons recalls ready-to-eat items in multiple states amid salmonella-linked jalapeño investigation

Albertsons Companies said it is voluntarily recalling four ready-to-eat products containing jalapeños supplied by Taylor Farms, including items sold at Randalls in Texas. The recall followed a supplier recall tied to an ongoing federal investigation and an FDA probe of a Salmonella Javiana outbreak. FDA reported 345 illnesses in 27 states, 36 hospitalizations, no deaths.

$CMGMed

Salmonella outbreak from Mexican jalapeños reported in 27 U.S. states

U.S. health authorities are investigating a Salmonella outbreak linked to Mexican jalapeño peppers. The CDC and FDA say 345 people are ill across 27 states, with 36 hospitalizations and no deaths. The supplier, Coast Citrus Distributors, recalled peppers sent to restaurants including Chipotle and QDOBA. Chipotle removed jalapeños from some outlets and shares fell over 8% on Aug. 4.